Dry Eye Syndrome Market Forecasts to 2028 – Global Analysis By Product (Anti-inflammatory Products, Artificial Tears, Punctal Plugs, Secretagogues, Oral Omega Supplements and Other Products), Type (Aqueous Deficient Dry Eye Syndrome and Evaporative Dry Ey

Dry Eye Syndrome Market Forecasts to 2028 – Global Analysis By Product (Anti-inflammatory Products, Artificial Tears, Punctal Plugs, Secretagogues, Oral Omega Supplements and Other Products), Type (Aqueous Deficient Dry Eye Syndrome and Evaporative Dry Eye Syndrome), Dosage Form (Eye Solutions, Eye Drops and Other Dosage Forms), Container Type, Distribution Channel and By Geography

According to Stratistics MRC, the Global Dry Eye Syndrome Market is accounted for $5.53 billion in 2022 and is expected to reach $9.69 billion by 2028 growing at a CAGR of 9.8% during the forecast period. The disorder known as dry eye syndrome, or keratoconjunctivitis sicca (KCS), is characterised by a lack of lubrication or moisture on the eye's surface. It is a widespread condition that can affect anyone at any time. Other dry eye symptoms include photophobia, aching and burning feelings, hurting eyes, red eyes, fatigued eyes, itchy eyes, and other eye-related issues. Watery eyes can also be a sign because the dryness of the eye's surface over-stimulates the creation of the watery component of tears.

According to the BMC Ophthalmology in February 2022, signs of eye dryness were reported in 5–30% of the elderly subjects, and the frequency of dry eye was 8.4% for those less than 60 years, 15% among 70-79 years, and 20% for patients over 80 years.

Market Dynamics

Driver

Rising rate of dry eye associated with masks

The rising incidence of Mask-Associated Dry Eye (MADE) is a significant market development. Face masks and face shields were essential in the fight against COVID-19, and the majority of ophthalmologists noticed that as a result of the prolonged usage of face masks and rise in screen time during the COVID-19 pandemic era, more and more patients began to have dry eyes. Additionally, it is anticipated that mask use will continue during the projection period as the prevalence of various infectious illnesses, particularly airborne infections, rises. During the projection period, this current tendency will accelerate the pace of acceptance of these goods and fuel market expansion.

Restraint

Ocular health isn't given much priority

The general public's perception of ocular health is one of the major issues restricting market growth. Because fewer people regularly see ophthalmologists, fewer people can be treated with these prescription medications. As a result, these eye care products are adopted at a lesser rate, which restricts the market's potential for growth. The prospective patient population's lower priority for ocular disorders such dry eye syndrome may impede the adoption rate of these treatments over the projected period, which would restrict the market's growth.

Opportunity

Strong R&D investments encourage potential candidates

Dry eye syndrome is becoming more common, which is fuelling the desire for effective therapy choices that improve patient outcomes. The market will expand as these goods become more widely available and more widely adopted. Several market participants are expanding their research efforts and concentrating on obtaining regulatory clearance of innovative medicinal treatments, which will fuel the expansion of the worldwide market during the forecast period.

Threat

Stringent regulations

However, the usage and adoption of these medications by the general public is constrained by the severe rules attached to them and the long-term treatment plans. The usual time for the treatment to start functioning is a few weeks, but it might take up to six months. Additionally, the medication may have adverse effects that impede market expansion.

Covid-19 Impact

Numerous investigations conducted during the COVID-19 epidemic discovered that COVID-19 patients continued to have dry eye symptoms for several weeks or months after they had recovered. As this is a prevalent ophthalmic disorder, this resulted in a rise in the prevalence of this ailment. Additionally, during the COVID-19, a gradual transition in people's work and study habits from offline to online led to a rise in the prevalence of this disorder. On the other hand, it was discovered that throughout the pandemic, consultations for all non-essential therapeutic interventions had decreased, which led to a fall in the demand for these therapies.

The anti-inflammatory products segment is expected to be the largest during the forecast period

The anti-inflammatory products segment is estimated to have a lucrative growth, due to they are used to moisturise eyes' outer surface and lubricate dry eye, ageing, usage of certain drugs, a medical condition, ocular surgery, and environmental factors including windy or smoky environments can all cause dry eyes. Artificial tears can be purchased over-the-counter. There is no one product that treats dry eyes the best in all cases. Additionally, non-prescription gels and gel implants for artificial tears are offered which drives the growth of the market.

The eye drops segment is expected to have the highest CAGR during the forecast period

The eye drops segment is anticipated to witness the highest CAGR growth during the forecast period, due to their simplicity of use and administration, eye drops have the highest revenue share. This enhanced patient compliance with treatment is a result. However, because the substance is being administered topically, its impact is less long-lasting and its removal is simple. In this market category, product launches are frequent and player migration is considerable.

Region with highest share

North America is projected to hold the highest market share during the forecast period owing to due to the rising incidence of this condition and the expanding use of medications for its treatment over the projection period. The demand for these treatment interventions is projected to increase as a result of this increased prevalence, boosting regional growth throughout the projection period.

Region with highest CAGR

Europe is projected to have the highest CAGR over the forecast period, owing to the increase in the number of geriatric people with this illness and rise in the disease burden there throughout the course of the projected period. The market participants will have a profitable chance to introduce new goods over the projected period thanks to this includes the rise in elderly patients with this ailment, which is projected to drive market expansion throughout the area.

Key players in the market

Some of the key players profiled in the Dry Eye Syndrome Market include Akorn , AFT Pharmaceuticals, Bausch Health Companies Inc., Mitotech, Johnson & Johnson, Otsuka Pharmaceutical Co. Ltd, Santen Pharmaceutical Co. Ltd, Sun Pharmaceutical Industries Ltd, Prestige Consumer Healthcare, OASIS Medical, Horus Pharma, AbbVie Inc. (Allergan PLC), VISUfarma, Novaliq GmbH, Alcon Inc., Pfizer Inc., Allostera Pharma Inc. Novartis AG and Teva Pharmaceutical Industries Ltd

Key Developments

In August 2022, Novaliq GmbH submitted New Drug Application (NDA) to the U.S. FDA for the approval for CyclASol (cyclosporine ophthalmic solution), which is a topical antiinflammatory and immunomodulating ophthalmic drug solution, developed for the treatment of dry eye disease.

In September 2021, Bausch Health Companies Inc. collaborated with Novaliq GmbH to develop the investigational drug NOV03 (perfluorohexyloctane), an eye drop used to treat the signs and symptoms of Dry Eye Disease (DED). The pipeline candidate is under phase 3 clinical study.

In April 2021, Alcon launched Systane Hydration Multi-dose preservative free lubricant eye drops in the U.S. market to provide long-lasting relief to patients with dry eyes.

Products Covered
• Anti-inflammatory Products
• Artificial Tears
• Punctal Plugs
• Secretagogues
• Oral Omega Supplements
• Other Products

Types Covered
• Aqueous Deficient Dry Eye Syndrome
• Evaporative Dry Eye Syndrome

Dosage Forms Covered
• Eye Solutions
• Eye Drops
• Capsules & Tablets
• Ointments
• Gels
• Other Dosage Forms

Container Types Covered
• Unit-Dose Vials
• Tubes
• Bottles

Distribution Channels Covered
• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies
• Other Distribution Channels

Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities,Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements